R

    Redhill Biopharma Ltd (RDHL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.90
    +0.24 (+36.16%)

    Market Cap: $4.02M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    39%(11/28)
    Avg Surprise
    -116.74%
    PeriodReportedEst.SurpriseB/MYoY
    Dec 25
    		$0.00$0.00N/ABeat+100.0%
    Sep 25
    		$0.00$0.00N/ABeat-
    Jun 25
    		$-2.29$0.00N/AMiss+98.9%
    Mar 25
    		$-4.02$0.00N/AMiss-1910.0%
    Dec 24
    		$-4.02$0.00N/AMiss-1910.0%
    Sep 24
    		$0.00$0.00N/ABeat-
    Jun 24
    		$-200.00$-30.00-566.67%Miss-78500.6%
    Mar 24
    		$-0.20$-0.03-566.67%Miss+87.5%
    Dec 23
    		$-0.20$-0.03-566.67%Miss+0.0%
    Sep 23
    		$0.00$0.00N/ABeat+100.0%
    Jun 23
    		$0.26$0.00N/ABeat+227.6%
    Mar 23
    		$-1.60$0.00N/ABeat+94.7%
    Dec 22
    		$-0.20$0.00N/AMiss+100.0%
    Sep 22
    		$-60.00$-10.00-500.00%Miss-20.0%
    Jun 22
    		$-0.20$-0.03-566.67%Miss+100.0%
    Mar 22
    		$-30.00$-30.00+0.00%Beat+94.0%
    Dec 21
    		$-500.00$-430.00-16.28%Miss-71328.6%
    Sep 21
    		$-50.00N/A+82.27%Beat+90.0%
    Jun 21
    		$-600.00$-248.00-141.94%Miss-1400.0%
    Mar 21
    		$-500.00$-278.00-79.86%Miss+0.0%
    Dec 20
    		$-0.70$-0.24-191.67%Miss+99.8%
    Sep 20
    		$-499.82$-185.00-170.17%Miss-66.6%
    Jun 20
    		$-40.00N/A+55.56%Beat+90.0%
    Mar 20
    		$-500.00$-600.00+16.67%Beat-66.7%
    Dec 19
    		$-300.00$-237.50-26.32%Miss-99900.0%
    Sep 19
    		$-300.00$-292.50-2.56%Miss+25.0%
    Jun 19
    		$-400.00$-346.67-15.38%Miss-79900.0%
    Mar 19
    		$-300.00$-346.67+13.46%Beat+40.0%
    Dec 18
    		$-0.30$-0.38+21.05%Beat+40.0%
    Sep 18
    		$-400.00$-413.33+3.23%Beat+55.6%
    Jun 18
    		$-0.50$-0.44-13.64%Miss+99.9%
    Mar 18
    		$-500.00$-463.33-7.91%Miss-99900.0%
    Dec 17
    		$-0.50$-0.60+16.67%Beat+99.9%
    Sep 17
    		$-900.00$-636.67-41.36%Miss-28.6%
    Jun 17
    		$-600.00$-620.00+3.23%Beat-
    Mar 17
    		$-0.50$-0.57+12.28%Beat-
    Dec 16
    		$-600.00$-693.33+13.46%Beat-
    Sep 16
    		$-700.00$-526.67-32.91%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDA0.30x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-150.00%Operating Margin-2765.00%
    ROE-1709.00%ROIC-145.68%
    Financial Health
    Debt/Equity0.04xInterest Coverage66.17x
    Current Ratio0.34xQuick Ratio0.34x
    Trading Statistics
    Beta4.90Avg Volume4.89M
    52-Week High$2.7952-Week Low$0.57

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.65
    SMA 20$0.63
    SMA 50$0.70
    SMA 200$0.94
    EMA 10$0.67
    EMA 20$0.66
    EMA 50$0.70
    EMA 200$1.01

    MACD

    Line: 0.01Signal: -0.02Hist: 0.03

    ADX

    ADX: 25.4+DI: 66.1-DI: 5.6

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down64.0
    PSAR$0.57

    Bollinger Bands

    Upper Band$0.77
    Lower Band$0.49
    %B Position4402%(Upper)
    Band Width1.49

    RSI (14-Day)

    Overbought
    76.3

    Momentum Oscillators

    Stoch %K59.0
    Stoch %D60.2
    Williams %R-68.0
    ROC (10d)53.8%
    Momentum0.32
    CCI (20d)609.8
    MFI (14d)99.9

    Volatility Measures

    ATR (14d)$0.11(12.4%)
    StdDev (20d)0.07
    Hist Vol143.7%(High)

    Volume Flow

    VWAP$1.13
    OBV241.1M
    AD Line-140.3M
    CMF (20d)-0.996

    Volume Metrics

    Avg Vol (20d)5.1M
    Vol Ratio19.9x(High)
    VWMA (20d)$0.90

    Pivot Points

    R3$0.78
    R2$0.74
    R1$0.70
    Pivot Point$0.66
    S1$0.62
    S2$0.58
    S3$0.54

    Advanced Oscillators

    TSI2.65
    Ultimate Osc32.3
    KST-59.06

    Financial Data

    QuarterJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total Revenue$2.04M$2.04M$2.74M$2.74M$1.29M$1.29M$567,500$567,500$1.80M$12.80M$12.80M$17.55M
    Cost of Revenue$803,500$803,500$894,000$894,000$702,000$702,000$520,499$520,499$806,000$8.60M$8.60M$9.45M
    Gross Profit$1.24M$1.24M$1.84M$1.84M$584,000$584,000$47,000$47,000$990,000$4.20M$4.20M$8.10M
    Operating Expenses$3.42M$3.42M$4.92M$4.92M$4.81M$4.81M$6.07M$6.07M$5.40M$14.15M$14.15M$15.21M
    R&D$482,000$482,000$464,500$464,500$329,500$329,500$598,500$598,500$1.25M$1.13M$1.13M$1.61M
    SG&A$1.93M$1.93M$3.28M$2.05M$2.73M$2.73M$6.00M$3.44M$3.54M$32.88M$32.88M$6.50M
    Operating Income$-2,189,000$-2,189,000$-3,082,500$-3,082,500$-4,224,000$-4,224,000$-6,020,000$-6,020,000$-4,408,000$-9,948,000$-9,948,000$-7,108,000
    Interest Income$0$0$913,000$0$0$0$1.04M$0$7.09M$21.58M$4.72M$3.19M
    Interest Expense$512,000$512,000$0$0$874,000$874,000$0$7.52M$1.93M$1.43M$1.43M$31.78M
    Income Before Tax$-2,066,500$-2,066,500$-2,590,000$-2,590,000$-1,544,000$-1,544,000$-13,543,000$-13,543,000$761,000$-3,729,000$-3,729,000$-35,701,000
    Income Tax Expense$0$0$0$0$0$0$0$0$421,000$-6,219,000$-6,219,000$28.59M
    Net Income$-2,066,500$-2,066,500$-2,590,000$-2,590,000$-1,544,000$-1,544,000$-13,543,000$-13,543,000$761,000$-3,729,000$2.49M$-35,701,000
    EBITDA$-2,105,000$-2,105,000$-1,878,500$-1,817,000$-4,014,999$-4,014,999$-5,841,500$-5,636,834$2.69M$-294,000$-294,000$-1,826,000
    EBIT$-2,189,000$-2,189,000$-1,903,000$-1,903,000$-4,223,999$-4,223,999$-6,020,000$-6,020,000$61.59M$-2,302,000$-9,948,000$-3,918,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RDHL

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Can RedHill Biopharma (NASDAQ:RDHL) Show Commercial Progress Today?

    RedHill Biopharma (NASDAQ:RDHL) is scheduled to report financial results today, placing scrutiny on its commercial execution, development programs, funding, and balance sheet. The article emphasizes that company-specific operational evidence regarding clinical and commercial progress, patient access, and cash discipline is more crucial than broad market assumptions. Readers should focus on qualitative signals like customer decisions, inventory movement, and alignment of capacity with demand to assess the company's real progress.

    Kalkine Media•8/20/26•
    Neutral

    RedHill Biopharma (RDHL) investors back all AGM resolutions in 2026

    RedHill Biopharma Ltd. announced that all resolutions proposed at its adjourned Annual General Meeting of Shareholders on August 7, 2026, were duly approved. This includes the re-appointment of auditors, re-election of board members, approval of Dror Ben-Asher as Chairman and CEO, and an amendment to the Company's Articles of Association. The company filed this report as a Form 6-K, which is incorporated by reference into several of its existing S-8 and F-3 registration statements.

    Stock Titan•8/7/26•
    Neutral

    RedHill Biopharma (NASDAQ: RDHL) adjourns AGM after quorum shortfall

    RedHill Biopharma Ltd. announced the adjournment of its Annual General Meeting of Shareholders, originally scheduled for August 6, 2026, due to a lack of a legal quorum. The meeting has been rescheduled to reconvene on August 7, 2026, at 3:00 p.m. Israel time at the company's Tel Aviv offices. This information, filed as a Form 6-K, is also incorporated by reference into several of the company's existing registration statements.

    Stock Titan•8/6/26•
    Neutral

    Redhill Biopharma Ltd (RDHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of Redhill Biopharma Ltd (RDHL), focusing on its stock price momentum, support and resistance levels, and various technical indicators. The current price momentum score is 4.70, ranking 44th in the Pharmaceuticals industry, with the stock trading between a resistance of $0.81 and a support of $0.56. While specific indicator values are provided (MACD, RSI, etc.), the overall signal based on moving averages and other technical indicators is Neutral.

    TradingKey•7/31/26•
    Neutral

    RedHill Biopharma (Nasdaq: RDHL) details opaganib plans amid Ebola surge

    RedHill Biopharma has provided an update on its investigational antiviral opaganib for Ebola virus disease, amidst a growing outbreak of Bundibugyo ebolavirus with over 3,200 cases and 1,400 deaths by July 28, 2026. The company is actively discussing next-step planning and potential partnerships with African health authorities and research institutions. Opaganib is highlighted for its oral, host-directed mechanism and previous positive results in severe COVID-19 and preclinical Ebola studies.

    Stock Titan•7/28/26•
    Somewhat-Bullish

    Frequently Asked Questions About RDHL

    Does RDHL pay dividends?
    Redhill Biopharma Ltd (RDHL) does not currently pay a regular dividend.
    What is RDHL's market cap?
    Redhill Biopharma Ltd (RDHL) has a market capitalization of $4.02M with a current stock price of $0.90.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In